EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fibroblast Growth Factor Receptor 4 Promotes Triple‐Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT/RYR2 Signaling

Jinhui Ye, Song Wu, Qiang Quan, Feng Ye iD, Jinhui Zhang, Cailu Song, Yidan Fan, Huijiao Cao, Hailin Tang iD, Jianfu Zhao

Cancer Medicine · 2024-12 · 13 (23)

DOI: 10.1002/cam4.70439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.12.2024. Verfasst von Jinhui Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Cancer Diagnosis and Therapy, Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptor, Fibroblast Growth Factor, Type 4, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Previous studies have found that fibroblast growth factor receptor 4 (FGFR4) plays a crucial role in tumor development and metastasis. However, the potential role and underlying mechanisms of FGFR4 in the progression of TNBC remain unclear.

Methods

Statistical analysis of FGFR4 expression data in public databases was used to reveal its role in TNBC. qRT‐PCR was used to detect FGFR4 expression levels. The impact of FGFR4 level changes on TNBC cell proliferation was assessed using CCK‐8 and colony formation assays, while Transwell invasion assays and JC‐1 staining were employed to analyze the effects of FGFR4 level changes on the invasiveness and survival capability of TNBC cells. Differentially expressed genes were subjected to Gene Ontology, KEGG, and GSEA enrichment analyses to identify associated signaling pathways. Additionally, Oil Red O staining, fatty acid metabolite detection, and Western blot analysis were used to investigate the impact of FGFR4 and its inhibitor fisogatinib, as well as the AKT activator SC79, on the metabolic reprogramming of fatty acids in TNBC cells.

Results

FGFR4 was found to be upregulated in breast cancer and correlated with poorer patient outcomes. Inhibition of FGFR4 resulted in reduced cell growth and invasion in TNBC cells. It also led to increased lipid accumulation, upregulated lipid biosynthesis‐related genes, and downregulated lipolysis‐related genes. Mechanistically, FGFR4 inhibition suppressed the activation of the AKT/RYR2 signaling pathway. Reactivating the AKT pathway reversed the suppressive effects of FGFR4 inhibition on TNBC progression.

Conclusion

Dysregulated FGFR4 activates the AKT/RYR2 axis, leading to tumor proliferation, invasion, and altered lipid metabolism in TNBC. FGFR4 inhibition could potentially serve as a novel therapeutic strategy for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsReceptor, Fibroblast Growth Factor, Type 4Proto-Oncogene Proteins c-aktSignal TransductionCell ProliferationFatty AcidsDisease ProgressionHumansFemaleCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

AKTFGFR4RyR2TNBCfatty acid metabolism

Substanzen

Receptor, Fibroblast Growth Factor, Type 4Proto-Oncogene Proteins c-aktFGFR4 protein, humanFatty Acids

Autor:innen und Institutionen

  • Research Center of Cancer Diagnosis and Therapy, Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Breast Oncology, The First People's Hospital of Zhaoqing, Zhaoqing, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

ORCID-Profile: Feng Ye, Hailin Tang

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Ye, J., Wu, S., Quan, Q., Ye, F., Zhang, J., Song, C., Fan, Y., Cao, H., Tang, H., & Zhao, J. (2024). Fibroblast Growth Factor Receptor 4 Promotes Triple‐Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT/RYR2 Signaling. Cancer Medicine, 13(23). https://doi.org/10.1002/cam4.70439

Vancouver

Ye J, Wu S, Quan Q, Ye F, Zhang J, Song C, et al. Fibroblast Growth Factor Receptor 4 Promotes Triple‐Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT/RYR2 Signaling. Cancer Medicine. 2024;13(23). doi:10.1002/cam4.70439

BibTeX
@article{Ye2024,
  author = {Ye, Jinhui and Wu, Song and Quan, Qiang and Ye, Feng and Zhang, Jinhui and Song, Cailu and Fan, Yidan and Cao, Huijiao and Tang, Hailin and Zhao, Jianfu},
  title = {Fibroblast Growth Factor Receptor 4 Promotes Triple‐Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT/RYR2 Signaling},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {23},
  doi = {10.1002/cam4.70439}
}
Kostenlos starten →